These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 30166257)

  • 21. A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma.
    Tuscano JM; Maverakis E; Groshen S; Tsao-Wei D; Luxardi G; Merleev AA; Beaven A; DiPersio JF; Popplewell L; Chen R; Kirschbaum M; Schroeder MA; Newman EM
    Clin Cancer Res; 2019 Dec; 25(23):7004-7013. PubMed ID: 31481504
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pixantrone beyond monotherapy: a review.
    Barrenetxea Lekue C; Grasso Cicala S; Leppä S; Stauffer Larsen T; Herráez Rodríguez S; Alonso Caballero C; Jørgensen JM; Toldbod H; Leal Martínez I; D'Amore F
    Ann Hematol; 2019 Sep; 98(9):2025-2033. PubMed ID: 31312929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma.
    Padrnos L; Ernst B; Dueck AC; Kosiorek HE; Ginos BF; Toro A; Johnston PB; Habermann TM; Leis JF; Mikhael JR; Nowakowski GS; Colgan J; Porrata L; Ansell SM; Witzig TE; Reeder C
    Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):664-672.e2. PubMed ID: 30104176
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan.
    Ogura M; Ishizawa K; Maruyama D; Uike N; Ando K; Izutsu K; Terui Y; Imaizumi Y; Tsukasaki K; Suzuki K; Izumi T; Usuki K; Kinoshita T; Taniwaki M; Uoshima N; Suzumiya J; Kurosawa M; Nagai H; Uchida T; Fukuhara N; Choi I; Ohmachi K; Yamamoto G; Tobinai K;
    Int J Hematol; 2017 Apr; 105(4):470-477. PubMed ID: 27900638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma.
    Belada D; Georgiev P; Dakhil S; Inhorn LF; Andorsky D; Beck JT; Quick D; Pettengell R; Daly R; Dean JP; Pavlyuk M; Failloux N; Hübel K
    Future Oncol; 2016 Aug; 12(15):1759-68. PubMed ID: 27093976
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma.
    Maddocks K; Christian B; Jaglowski S; Flynn J; Jones JA; Porcu P; Wei L; Jenkins C; Lozanski G; Byrd JC; Blum KA
    Blood; 2015 Jan; 125(2):242-8. PubMed ID: 25355819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
    Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
    Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis.
    Hong JY; Yoon DH; Suh C; Kim WS; Kim SJ; Jo JC; Kim JS; Lee WS; Oh SY; Park Y; Kim SY; Lee MH; Lee HS; Do YR
    Ann Hematol; 2018 Aug; 97(8):1437-1443. PubMed ID: 29619501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma.
    Kelly KR; Friedberg JW; Park SI; McDonagh K; Hayslip J; Persky D; Ruan J; Puvvada S; Rosen P; Iyer SP; Stefanovic A; Bernstein SH; Weitman S; Karnad A; Monohan G; VanderWalde A; Mena R; Schmelz M; Spier C; Groshen S; Venkatakrishnan K; Zhou X; Sheldon-Waniga E; Leonard EJ; Mahadevan D
    Clin Cancer Res; 2018 Dec; 24(24):6150-6159. PubMed ID: 30082475
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial.
    Peñalver FJ; Márquez JA; Durán S; Giraldo P; Martín A; Montalbán C; Sancho JM; Ramírez MJ; Terol MJ; Capote FJ; Gutiérrez A; Sánchez B; López A; Salar A; Rodríguez-Caravaca G; Canales M; Caballero MD;
    Cancer Med; 2019 Nov; 8(16):6955-6966. PubMed ID: 31573746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
    Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
    Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial.
    Budde LE; Wu D; Martin DB; Philip M; Shustov AR; Smith SD; Gooley TA; Chen TL; Libby EN; Chen EY; Kojouri K; Langerak A; Roden JE; Press OW; Gopal AK
    Br J Haematol; 2018 Nov; 183(4):601-607. PubMed ID: 30596402
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma.
    Ogura M; Tobinai K; Hatake K; Davies A; Crump M; Ananthakrishnan R; Ishibashi T; Paccagnella ML; Boni J; Vandendries E; MacDonald D
    Clin Cancer Res; 2016 Oct; 22(19):4807-4816. PubMed ID: 27154915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
    Harting R; Venugopal P; Gregory SA; O'brien T; Bogdanova E
    Clin Lymphoma Myeloma; 2007 May; 7(6):406-12. PubMed ID: 17621406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial.
    Pettengell R; Coiffier B; Narayanan G; de Mendoza FH; Digumarti R; Gomez H; Zinzani PL; Schiller G; Rizzieri D; Boland G; Cernohous P; Wang L; Kuepfer C; Gorbatchevsky I; Singer JW
    Lancet Oncol; 2012 Jul; 13(7):696-706. PubMed ID: 22652183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lymphoma: a multicenter phase II study.
    Sakai R; Ohmachi K; Sano F; Watanabe R; Takahashi H; Takasaki H; Tanaka M; Hattori Y; Kimura H; Takimoto M; Tachibana T; Tanaka E; Ishii Y; Ishiyama Y; Hagihara M; Miyazaki K; Yamamoto K; Tomita N; Ando K
    Ann Hematol; 2019 Sep; 98(9):2131-2138. PubMed ID: 31286196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study.
    Matsumoto Y; Kobayashi T; Shimura Y; Kawata E; Nagoshi H; Ohshiro M; Sugitani M; Shimura K; Iwai T; Fuchida SI; Yoshida M; Kiyota M; Mizutani S; Chinen Y; Takimoto-Shimomura T; Nakao M; Kaneko H; Uchiyama H; Uoshima N; Nishigaki H; Kobayashi Y; Horiike S; Shimazaki C; Taniwaki M; Kuroda J;
    Int J Hematol; 2019 Jul; 110(1):77-85. PubMed ID: 31127456
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
    Ohmachi K; Ando K; Ogura M; Uchida T; Itoh K; Kubota N; Ishizawa K; Yamamoto J; Watanabe T; Uike N; Choi I; Terui Y; Usuki K; Nagai H; Uoshima N; Tobinai K;
    Cancer Sci; 2010 Sep; 101(9):2059-64. PubMed ID: 20626754
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma.
    Beaven AW; Shea TC; Moore DT; Feldman T; Ivanova A; Ferraro M; Ford P; Smith J; Goy A
    Leuk Lymphoma; 2012 Feb; 53(2):254-8. PubMed ID: 21812533
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.
    Damaj G; Gressin R; Bouabdallah K; Cartron G; Choufi B; Gyan E; Banos A; Jaccard A; Park S; Tournilhac O; Schiano-de Collela JM; Voillat L; Joly B; Le Gouill S; Saad A; Cony-Makhoul P; Vilque JP; Sanhes L; Schmidt-Tanguy A; Bubenheim M; Houot R; Diouf M; Marolleau JP; Béné MC; Martin A; Lamy T
    J Clin Oncol; 2013 Jan; 31(1):104-10. PubMed ID: 23109692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.